{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T04:39:24Z","timestamp":1786250364850,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000866","name":"International Aids Vaccine Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203311"],"award-info":[{"award-number":["NIHR203311"]}],"id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020171","name":"Foreign, Commonwealth and Development Office","doi-asserted-by":"publisher","award":["MR\/N023668\/1"],"award-info":[{"award-number":["MR\/N023668\/1"]}],"id":[{"id":"10.13039\/501100020171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["681137-EAVI2020"],"award-info":[{"award-number":["681137-EAVI2020"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007936","name":"International AIDS Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007936","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["SRIA2015-1066"],"award-info":[{"award-number":["SRIA2015-1066"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Microbe"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.lanmic.2024.100956","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T14:21:17Z","timestamp":1732630877000},"page":"100956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and immunogenicity of the ChAdOx1\u2013MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1\u00a0trial in adults living without HIV-1 in\u00a0the UK"],"prefix":"10.1016","volume":"6","author":[{"given":"Nicola","family":"Borthwick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4213-079X","authenticated-orcid":false,"given":"Natalia","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1251-934X","authenticated-orcid":false,"given":"Peter J","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund G-T","family":"Wee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belkis M","family":"Akis Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Baines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Byard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Glaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Jenkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2668-4709","authenticated-orcid":false,"given":"Colin","family":"Larkworthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Luciw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Poulton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merin","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Quaddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8570-2113","authenticated-orcid":false,"given":"Marion","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Crook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cicconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6076-9546","authenticated-orcid":false,"given":"Tom\u00e1\u0161","family":"Hanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanmic.2024.100956_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104557","article-title":"Primary role of type I\u00a0interferons for the induction of functionally optimal antigen-specific CD8+ T\u00a0cells in HIV infection","volume":"91","author":"Cabral-Piccin","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.lanmic.2024.100956_bib2","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1126\/science.1143767","article-title":"A\u00a0whole-genome association study\u00a0of major determinants for host control of HIV-1","volume":"317","author":"Fellay","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.lanmic.2024.100956_bib3","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.immuni.2012.09.005","article-title":"HIV and HLA class I: an evolving relationship","volume":"37","author":"Goulder","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.lanmic.2024.100956_bib4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/1479-5876-9-208","article-title":"Definition of the viral targets of protective HIV-1-specific T\u00a0cell responses","volume":"9","author":"Mothe","year":"2011","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.lanmic.2024.100956_bib5","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1126\/science.1195271","article-title":"The major genetic determinants of HIV-1 control affect HLA class I\u00a0peptide presentation","volume":"330","author":"Pereyra","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.lanmic.2024.100956_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02142-18","article-title":"Effective suppression of HIV-1\u00a0replication by cytotoxic T\u00a0lymphocytes specific for Pol epitopes in conserved mosaic vaccine immunogens","volume":"93","author":"Zou","year":"2019","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.lanmic.2024.100956_bib7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14760584.2019.1675518","article-title":"Aiming for protective T-cell responses: a focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials","volume":"18","author":"Hanke","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.lanmic.2024.100956_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/vir.0.82493-0","article-title":"Clinical experience with plasmid DNA- and modified vaccinia vaccine Ankara (MVA)-vectored HIV-1 clade A\u00a0vaccine inducing T\u00a0cells","volume":"88","author":"Hanke","year":"2007","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.lanmic.2024.100956_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078289","article-title":"A\u00a0phase I\u00a0randomized clinical trial of candidate human immunodeficiency virus type 1\u00a0vaccine MVA.HIVA administered to Gambian infants","volume":"8","author":"Afolabi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.lanmic.2024.100956_bib50","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1016\/j.vaccine.2014.08.034","article-title":"PedVacc 002: a phase I\/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi","volume":"32","author":"Njuguna","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.lanmic.2024.100956_bib8","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/79626","article-title":"Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya","volume":"6","author":"Hanke","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.lanmic.2024.100956_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000984","article-title":"Design and pre-clinical evaluation of a universal HIV-1 vaccine","volume":"2","author":"L\u00e9tourneau","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.lanmic.2024.100956_bib10","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3389\/fimmu.2020.00823","article-title":"HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals: Safety, immunogenicity and effect on the viral reservoir (study BCN 02)","volume":"11","author":"Mothe","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.lanmic.2024.100956_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103956","article-title":"Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome","volume":"78","author":"Oriol-Tordera","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.lanmic.2024.100956_bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40168-022-01247-6","article-title":"Gut microbiome signatures linked to HIV-1 reservoir size and viremia control","volume":"10","author":"Borgognone","year":"2022","journal-title":"Microbiome"},{"key":"10.1016\/j.lanmic.2024.100956_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104732","article-title":"Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination","volume":"95","author":"Duran-Castells","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.lanmic.2024.100956_bib14","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/mt.2016.3","article-title":"Novel conserved-region T-cell mosaic vaccine with high global HIV-1 coverage is recognized\u00a0by protective responses in untreated infection","volume":"24","author":"Ondondo","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.lanmic.2024.100956_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12977-018-0429-y","article-title":"CD8+ T\u00a0cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication","volume":"15","author":"Murakoshi","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.lanmic.2024.100956_bib16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12967-015-0392-5","article-title":"A\u00a0human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques","volume":"13","author":"Mothe","year":"2015","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.lanmic.2024.100956_bib17","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1038\/s41591-022-02060-2","article-title":"Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1\u00a0trial","volume":"28","author":"Bail\u00f3n","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.lanmic.2024.100956_bib18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nm1461","article-title":"Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants","volume":"13","author":"Fischer","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.lanmic.2024.100956_bib21","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1089\/aid.2015.0074","article-title":"Optimized replicating Renilla luciferase reporter HIV-1 utilizing novel internal ribosome entry site elements for native Nef expression and function","volume":"31","author":"Alberti","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.lanmic.2024.100956_bib22","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2031499","article-title":"Vaccine efficacy of ALVAC-HIV\u00a0and bivalent subtype C\u00a0gp120-MF59\u00a0in adults","volume":"384","author":"Gray","year":"2021","journal-title":"N\u00a0Engl J\u00a0Med"},{"key":"10.1016\/j.lanmic.2024.100956_bib46","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","article-title":"HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis","volume":"372","author":"McElrath","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2024.100956_bib47","series-title":"HIV Vaccine Trials Network","article-title":"Phase 3 mosaic-based investigational HIV vaccine study discontinued following disappointing results of planned data review. HIV Vaccine Trials Network","year":"2023"},{"key":"10.1016\/j.lanmic.2024.100956_bib23","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/21645515.2019.1666957","article-title":"T\u00a0cell-based strategies for HIV-1 vaccines","volume":"16","author":"Korber","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.lanmic.2024.100956_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260118","article-title":"Breadth of CD8 T-cell mediated inhibition of replication of diverse HIV-1 transmitted-founder isolates correlates with the breadth of recognition within a comprehensive HIV-1 Gag, Nef, Env and Pol potential T-cell epitope (PTE) peptide set","volume":"16","author":"Hayes","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.lanmic.2024.100956_bib25","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/infdis\/jit322","article-title":"Vaccine-induced gag-specific T\u00a0cells are associated with reduced viremia after HIV-1 infection","volume":"208","author":"Janes","year":"2013","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.lanmic.2024.100956_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013579","article-title":"Safety and immunogenicity of a replication-defective adenovirus type 5\u00a0HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054)","volume":"5","author":"Peiperl","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.lanmic.2024.100956_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/ni1281","article-title":"Control of human immunodeficiency virus replication by cytotoxic T\u00a0lymphocytes targeting subdominant epitopes","volume":"7","author":"Frahm","year":"2006","journal-title":"Nat Immunol"},{"key":"10.1016\/j.lanmic.2024.100956_bib28","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1084\/jem.20090365","article-title":"The first T\u00a0cell response to transmitted\/founder virus contributes to the control of acute viremia in HIV-1 infection","volume":"206","author":"Goonetilleke","year":"2009","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.lanmic.2024.100956_bib29","first-page":"380","article-title":"Vertical T\u00a0cell immunodominance and epitope entropy determine HIV-1 escape","volume":"123","author":"Liu","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.lanmic.2024.100956_bib30","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1086\/650492","article-title":"Viral inhibition assay: a CD8 T\u00a0cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates","volume":"201","author":"Spentzou","year":"2010","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.lanmic.2024.100956_bib31","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/infdis\/jis379","article-title":"Antiviral inhibitory capacity of CD8+ T\u00a0cells predicts the rate of CD4+ T-cell decline in HIV-1 infection","volume":"206","author":"Yang","year":"2012","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.lanmic.2024.100956_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/MMBR.00155-20","article-title":"The CD8+ T\u00a0cell noncytotoxic antiviral responses","volume":"85","author":"Morvan","year":"2021","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.lanmic.2024.100956_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1029029","article-title":"Assessment of a diverse panel of transmitted\/founder HIV-1 infectious molecular clones in a luciferase based CD8 T-cell mediated viral inhibition assay","volume":"13","author":"Fernandez","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.lanmic.2024.100956_bib33","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1073\/pnas.0611244104","article-title":"HIV controllers exhibit potent CD8 T\u00a0cell capacity to suppress HIV infection ex\u00a0vivo and peculiar cytotoxic T\u00a0lymphocyte activation phenotype","volume":"104","author":"S\u00e1ez-Ciri\u00f3n","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.lanmic.2024.100956_bib34","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1128\/jvi.71.4.3120-3128.1997","article-title":"Suppression of human immunodeficiency virus type 1\u00a0replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms","volume":"71","author":"Yang","year":"1997","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.lanmic.2024.100956_bib35","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1097\/QAD.0000000000001122","article-title":"Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T\u00a0cells with limited breadth of HIV-1 inhibition","volume":"30","author":"Hayes","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.lanmic.2024.100956_bib36","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20070784","article-title":"Superior control of HIV-1 replication by CD8+ T\u00a0cells is reflected by their avidity, polyfunctionality, and clonal turnover","volume":"204","author":"Almeida","year":"2007","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.lanmic.2024.100956_bib37","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1128\/JVI.02362-06","article-title":"Epitope-dependent avidity thresholds for cytotoxic T-lymphocyte clearance of virus-infected cells","volume":"81","author":"Bennett","year":"2007","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.lanmic.2024.100956_bib38","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.4049\/jimmunol.166.3.1690","article-title":"High-avidity CTL\u00a0exploit two complementary mechanisms to provide better protection\u00a0against viral infection than low-avidity CTL","volume":"166","author":"Derby","year":"2001","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.lanmic.2024.100956_bib39","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1126\/science.1076064","article-title":"Direct link between mhc polymorphism, T\u00a0cell avidity, and diversity in immune defense","volume":"298","author":"Messaoudi","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.lanmic.2024.100956_bib40","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1084\/jem.20051357","article-title":"Avidity for antigen shapes clonal dominance in CD8+ T\u00a0cell populations specific for persistent DNA viruses","volume":"202","author":"Price","year":"2005","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.lanmic.2024.100956_bib41","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.immuni.2023.04.010","article-title":"Recruitment of epitope-specific T\u00a0cell clones with a low-avidity threshold supports\u00a0efficacy against mutational escape upon re-infection","volume":"56","author":"Straub","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.lanmic.2024.100956_bib42","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1182\/blood-2005-12-4818","article-title":"HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T\u00a0cells","volume":"107","author":"Betts","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.lanmic.2024.100956_bib43","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ni845","article-title":"HIV-specific CD8+ T\u00a0cell proliferation is coupled to perforin expression and is maintained in nonprogressors","volume":"3","author":"Migueles","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.lanmic.2024.100956_bib44","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/COH.0000000000000523","article-title":"Everything in its right place: resident memory CD8+ T\u00a0cell immunosurveillance of HIV infection","volume":"14","author":"Buggert","year":"2019","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.lanmic.2024.100956_bib45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/vaccines8010028","article-title":"Novel nested peptide epitopes recognized by CD4+ T\u00a0cells\u00a0induced by HIV-1 conserved-region vaccines","volume":"8","author":"Borthwick","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.lanmic.2024.100956_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1186478","article-title":"Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T\u00a0cells in the mucosa","volume":"14","author":"Beavis","year":"2023","journal-title":"Front Immunol"}],"container-title":["The Lancet Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266652472400209X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266652472400209X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T21:51:37Z","timestamp":1762638697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266652472400209X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S266652472400209X"],"URL":"https:\/\/doi.org\/10.1016\/j.lanmic.2024.100956","relation":{},"ISSN":["2666-5247"],"issn-type":[{"value":"2666-5247","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of the ChAdOx1\u2013MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1\u00a0trial in adults living without HIV-1 in\u00a0the UK","name":"articletitle","label":"Article Title"},{"value":"The Lancet Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2024.100956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100956"}}